In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Jason Hawkes, MD, MS, for a special Tea with Dr. D edition exploring the immunology that underpins inflammatory skin disease and how a deeper understanding of cytokine biology can inform clinical decision-making.The discussion begins by challenging the common tendency to classify diseases according to a single "dominant" cytokine or immune pathway. Drs Del Rosso and Hawkes emphasize that while frameworks such as type 1, type 2, and type 3 inflammation are valuable for organizing complex biology, they should be viewed as conceptual models rather than rigid categories, as immune responses are dynamic, overlapping, and highly interconnected.Using a series of educational slides, Dr Hawkes reviews how naïve T cells differentiate into distinct immune responses after interacting with antigen-presenting cells within the lymph node. He highlights 3 key cytokines that help clinicians remember the major pathways driving differentiation: IL-12 for type 1 inflammation, IL-4 for type 2 inflammation, and IL-23 for type 3 inflammation. These regulatory cytokines shape downstream immune responses that ultimately contribute to diseases such as atopic dermatitis and psoriasis.A major focus of the episode is the distinct but complementary roles of IL-4 and IL-13 in type 2 inflammation. Dr Hawkes explains why IL-4 serves as the critical regulator of type 2 immune differentiation, functioning within the lymph node to establish the broader immune response, while IL-13 plays a prominent role within peripheral tissues, particularly the skin. He also addresses the misconception that higher tissue expression necessarily indicates greater biologic importance, noting that cytokines often exert profound effects despite relatively low expression levels.Throughout the discussion, the speakers reinforce that cytokines should not be viewed in isolation. Their overlapping and synergistic effects help explain why patients can present with different clinical manifestations despite sharing common inflammatory mechanisms. Ultimately, the goal is not to identify a universally superior therapeutic target, but to understand each patient's disease biology well enough to select the therapy that best matches their clinical presentation.Tune in to the full episode to learn more about the foundations of type 1, type 2, and type 3 inflammation, the distinct roles of key cytokines in immune regulation and tissue disease, common misconceptions surrounding cytokine biology, and how a stronger understanding of immunology can support more personalized treatment decisions in everyday dermatology practice.